Progress of clinical trials for immunotherapy drugs in advanced esophageal cancer
- VernacularTitle:晚期食管癌免疫治疗药物及临床试验进展
- Author:
Xuefeng LENG
1
,
2
;
Qiyu LUO
1
,
2
;
Yongtao HAN
1
,
2
Author Information
1. Division of Thoracic Surgery, Sichuan Cancer Hospital &
2. Research Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, P.R.China
- Publication Type:Journal Article
- Keywords:
Esophageal cancer;
immunotherapy;
clinical trials;
clinical guidelines;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2020;27(07):834-839
- CountryChina
- Language:Chinese
-
Abstract:
Early and mid-stage esophageal cancer can achieve a particular effect through surgeries or comprehensive treatment based on surgery. Once the esophageal cancer progresses to the advanced stage, it is still lack of effective remedy for the disease, and the patient's prognosis is poor. Immunotherapy has developed rapidly in recent years, bringing dawn to patients with advanced esophageal cancer. On July 31, 2019, the US Food and Drug Administration (FDA) approved KEYTRUDA (Merck) for the treatment of esophageal squamous cell carcinoma, and it became the first milestone drug for esophageal squamous cell carcinoma. In the paper, we will review the progress of immunotherapy in the treatment of advanced esophageal cancer on the basis of current clinical researches, which might provide ideas for further studies in the immunotherapy for esophageal cancer.
